Literature DB >> 18349319

Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.

Yung-Chi Chang1, Tse-Ching Chen, Chun-Ting Lee, Chih-Ya Yang, Hsei-Wei Wang, Chao-Ching Wang, Shie-Liang Hsieh.   

Abstract

Decoy receptor 3 (DcR3) is a member of the TNF receptor superfamily and is up-regulated in tumors originating from a diversity of lineages. DcR3 is capable of promoting angiogenesis, inducing dendritic cell apoptosis, and modulating macrophage differentiation. Since tumor-associated macrophages (TAMs) are the major infiltrating leukocytes in most malignant tumors, we used microarray technology to investigate whether DcR3 contributes to the development of TAMs. Among the DcR3-modulated genes expressed by TAMs, those that encode proteins involved in MHC class II (MHC-II)-dependent antigen presentation were down-regulated substantially, together with the master regulator of MHC-II expression (the class II transactivator, CIITA). The ERK- and JNK-induced deacetylation of histones associated with the CIITA promoters was responsible for DcR3-mediated down-regulation of MHC-II expression. Furthermore, the expression level of DcR3 in cancer cells correlated inversely with HLA-DR levels on TAMs and with the overall survival time of pancreatic cancer patients. The role of DcR3 in the development of TAMs was further confirmed using transgenic mice overexpressing DcR3. This elucidates the molecular mechanism of impaired MHC-II-mediated antigen presentation by TAMs, and raises the possibility that subversion of TAM-induced immunosuppression via inhibition of DcR3 expression might represent a target for the design of new therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349319     DOI: 10.1182/blood-2007-12-130609

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation.

Authors:  Suhnrita Chaudhuri; Manoj Kumar Singh; Debanjan Bhattacharya; Sagar Acharya; Sirshendu Chatterjee; Pankaj Kumar; Pushpak Bhattacharjee; Anjan Kumar Basu; Gaurisankar Sa; Tanya Das; Tushar Kanti Ghosh; Swapna Chaudhuri
Journal:  J Neurooncol       Date:  2014-07-16       Impact factor: 4.130

Review 2.  The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.

Authors:  Kelly J Lafaro; Laleh G Melstrom
Journal:  Am J Pathol       Date:  2019-01       Impact factor: 4.307

3.  Monocytes to functional dendritic cells is often a bridge too far for cancer therapy.

Authors:  William F Carson; Steven L Kunkel
Journal:  Transl Res       Date:  2011-05-13       Impact factor: 7.012

4.  DcR3 suppresses influenza virus-induced macrophage activation and attenuates pulmonary inflammation and lethality.

Authors:  Ming-Ting Huang; Szu-Ting Chen; Hsin-Yi Wu; Yu-Ju Chen; Teh-Ying Chou; Shie-Liang Hsieh
Journal:  J Mol Med (Berl)       Date:  2015-05-05       Impact factor: 4.599

5.  Aberrant DNA methylation profile in cholangiocarcinoma.

Authors:  Li Huang; Gabriel Frampton; Li-Jian Liang; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

6.  Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

Authors:  Deepa Kolaseri Krishnadas; Lei Bao; Fanqi Bai; Satheesh Cheeyancheri Chencheri; Kenneth Lucas
Journal:  Tumour Biol       Date:  2014-03-02

7.  PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.

Authors:  C A Crane; A Panner; J C Murray; S P Wilson; H Xu; L Chen; J P Simko; F M Waldman; R O Pieper; A T Parsa
Journal:  Oncogene       Date:  2008-10-13       Impact factor: 9.867

Review 8.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

Review 9.  Role of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection.

Authors:  Alison J Eastman; John J Osterholzer; Michal A Olszewski
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.